Courage Capital Management’s Matinas BioPharma MTNB Stock Holding History

Courage Capital Management’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-6,637	Closed	-$119K	–	15
2023 Q2	$119K	Hold	6,637	–	–	0.33%	17
2023 Q1	$156K	Hold	6,637	–	–	0.37%	17
2022 Q4	$166K	Hold	6,637	–	–	0.47%	18
2022 Q3	$211K	Hold	6,637	–	–	0.46%	18
2022 Q2	$262K	Sell	6,637 -13,363	-67%	-$509K	0.43%	22
2022 Q1	$804K	Sell	20,000 -18,000	-47%	-$662K	0.77%	27
2021 Q4	$1.92M	Buy	38,000 +4,000	+12%	+$214K	1.27%	20
2021 Q3	$2.21M	Buy	34,000 +4,000	+13%	+$173K	1.18%	19
2021 Q2	$1.16M	Buy	+30,000	New	+$1.29M	0.69%	24

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Courage Capital Management's MTNB Position: Q3 2023 in Review

Courage Capital Management sold out of Matinas BioPharma (MTNB) in Q3 2023, closing a stake of 6,637 shares — an estimated $119K sold.

Courage Capital Management first reported a position in MTNB in Q2 2021 and held it in 9 quarters. The position peaked at $2.21M in Q3 2021. 47 funds tracked by Wall St. Rank hold MTNB as of Q3 2023.

Courage Capital Management reported no remaining Matinas BioPharma position as of Q3 2023 after selling out during the quarter.
Courage Capital Management sold 6,637 Matinas BioPharma shares in Q3 2023, an estimated $119K.
Courage Capital Management first reported a position in Matinas BioPharma in Q2 2021 and held it in 9 quarters.
Courage Capital Management's Matinas BioPharma position peaked at $2.21M in Q3 2021.
47 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2023.

Based on Courage Capital Management's 13F filing for Q3 2023, filed 8 Nov 2023.